Over the past several decades, tremendous progress has been made in the treatment of
follicular lymphoma. The addition of rituximab to chemotherapy led to significant …

Follicular lymphoma (FL) is the second most frequent B-cell non-Hodgkin's lymphoma (NHL)
with an incidence of 2.7 per 100 000 persons in the United States per year (https://seer …

Opinion Statement The optimal initial treatment of follicular lymphoma (FL) is not known, and
initial management of patients varies considerably between providers and institutions. The …

Abstract Disease Overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …

The landscape of treatment of follicular lymphoma is fast-changing. In the pre-rituximab era,
there was little evidence of improved outcomes with the use of aggressive anthracycline …

Despite remaining an incurable disease, overall survival improvements have been noted in
patients with advanced-stage follicular lymphoma. The Follicular Lymphoma International …

Disease overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …

It is important to consider all of these factors because they are often predictive of response to
the next line of therapy. For example, if a patient was treated with rituximab monotherapy …

Simple Summary Follicular lymphoma (FL)—a common, indolent, and usually non-curable B-
cell non-Hodgkin lymphoma—is frequently treated with cytotoxic chemotherapy with anti …

Over the last three decades, there has been a wide range of options in the management of
follicular lymphoma, including observation (watching and waiting), single-agent or …